Bradner, James E.

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature

Protein Degradation and InhibitorsChromatin Remodeling and Cancer

Cited by 4,262

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell

Protein Degradation and InhibitorsChromatin Remodeling and Cancer

Cited by 2,961

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature

Protein Degradation and InhibitorsAcute Myeloid Leukemia Research

Cited by 1,870

Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 1,760

HDAC2 negatively regulates memory formation and synaptic plasticity

Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature

Histone Deacetylase Inhibitors ResearchMemory and Neural Mechanisms

Cited by 1,644

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 1,583

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling

Su, R., Dong, L., Li, C., Nachtergaele, S., Wunderlich, M., Qing, Y., Deng, X., Wang, Y., Weng, X., Hu, C., et al. (2018) · Cell

RNA modifications and cancerAcute Myeloid Leukemia Research

Cited by 1,137

The dTAG system for immediate and target-specific protein degradation

Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 1,118

YY1 Is a Structural Regulator of Enhancer-Promoter Loops

Weintraub, A. S., Li, C. H., Zamudio, A. V., Sigova, A. A., Hannett, N. M., Day, D. S., Abraham, B. J., Cohen, M. A., Nabet, B., Buckley, D. L., et al. (2017) · Cell

Genomics and Chromatin DynamicsChromatin Remodeling and Cancer

Cited by 992

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science

Glioma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 938

Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset

Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery

Computational Drug Discovery MethodsCancer Genomics and Diagnostics

Cited by 813

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry

Heat shock proteins researchHistone Deacetylase Inhibitors Research

Cited by 755

Direct inhibition of the NOTCH transcription factor complex

Moellering, R. E., Cornejo, M., Davis, T. N., Bianco, C. D., Aster, J. C., Blacklow, S. C., Kung, A. L., Gilliland, D. G., Verdine, G. L., & Bradner, J. E. (2009) · Nature

Chemical Synthesis and AnalysisRNA Interference and Gene Delivery

Cited by 752

Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell

Protein Degradation and InhibitorsChromatin Remodeling and Cancer

Cited by 735

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 730

Chemical phylogenetics of histone deacetylases

Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology

Histone Deacetylase Inhibitors ResearchEnzyme function and inhibition

Cited by 720

MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

Kryukov, G. V., Wilson, F. H., Ruth, J. R., Paulk, J., Tsherniak, A., Marlow, S. E., Vazquez, F., Weir, B. A., Fitzgerald, M. E., Tanaka, M., et al. (2016) · Science

Cancer-related gene regulationChromatin Remodeling and Cancer

Cited by 688

A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia

Gröschel, S., Sanders, M. A., Hoogenboezem, R., de Wit, E., Bouwman, B. A. M., Erpelinck, C., van der Velden, V. H. J., Havermans, M., Avellino, R., van Lom, K., et al. (2014) · Cell

Acute Myeloid Leukemia ResearchGenomics and Chromatin Dynamics

Cited by 687

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature

Protein Degradation and InhibitorsChromatin Remodeling and Cancer

Cited by 632

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood

Multiple Myeloma Research and TreatmentsHistone Deacetylase Inhibitors Research

Cited by 616

Plasticity in binding confers selectivity in ligand-induced protein degradation

Nowak, R. P., DeAngelo, S. L., Buckley, D., He, Z., Donovan, K. A., An, J., Safaee, N., Jedrychowski, M. P., Ponthier, C. M., Ishoey, M., et al. (2018) · Nature Chemical Biology

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 615

NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis

Brown, J. D., Lin, C. Y., Duan, Q., Griffin, G., Federation, A. J., Paranal, R. M., Bair, S., Newton, G., Lichtman, A. H., Kung, A. L., et al. (2014) · Molecular Cell

Genomics and Chromatin DynamicsNF-κB Signaling Pathways

Cited by 614

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

Olson, C. M., Jiang, B., Erb, M. A., Liang, Y., Doctor, Z. M., Zhang, Z., Zhang, T., Kwiatkowski, N., Boukhali, M., Green, J. L., et al. (2018) · Nature Chemical Biology

Protein Degradation and InhibitorsHistone Deacetylase Inhibitors Research

Cited by 552

Quantitative ChIP-Seq normalization reveals global modulation of the epigenome

Orlando, D. A., Chen, M. W., Brown, V. E., Solanki, S., Choi, Y. J., Olson, E. R., Fritz, C. C., Bradner, J. E., & Guenther, M. G. (2014) · Cell Reports

Genomics and Chromatin DynamicsEpigenetics and DNA Methylation

Cited by 503